0006-3029 : Keytruda 50 mg/2ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: | 0006-3029 |
Labeler: | Merck Sharp & Dohme Corp. |
Product Type: | Human Prescription Drug |
Drug Name: | Keytruda |
Dosage Form: | Intravenous Injection, Powder, Lyophilized, for Solution |
Application #: | BLA125514 |
Rev. Date: |
NDC Package Codes:
- 0006-3029-02: 1 VIAL IN 1 CARTON (0006‑3029‑02) > 15 ML IN 1 VIAL (0006‑3029‑01)
Active Ingredients:
- Pembrolizumab
Dosage Strength:
- 50 mg/2mL
Pharmaceutical Classes:
- Programmed Death Receptor-1 Blocking Antibody [EPC]
- Programmed Death Receptor-1-directed Antibody Interactions [MoA]
Related Products:
Based on records with the same trade name.- 0006-3026 Keytruda 25 mg/ml Intravenous Injection, Solution by Merck Sharp & Dohme Corp.
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 0006-3026Next: 0006-3061 >
Related Discussions:
Keytruda vs Ippy
I just failed Ippy. Now my oncologist wants to start Keytruda 1/16/15. Those of you who have been on Keytruda for awhile... 4 replies
I just failed Ippy. Now my oncologist wants to start Keytruda 1/16/15. Those of you who have been on Keytruda for awhile... 4 replies
Thyroid cancer and KEYTRUDA
I have stage 4 thyroid cancer which has metastasized to my lungs. Although it is slow growing, the cancer will kill me. ... 28 replies
I have stage 4 thyroid cancer which has metastasized to my lungs. Although it is slow growing, the cancer will kill me. ... 28 replies
Pembrolizumab and Glutathione
My husband is in immunotherapy, undergoing 1 infusion of pembrolizumab ('Keytruda') every three weeks. Is it hel...
My husband is in immunotherapy, undergoing 1 infusion of pembrolizumab ('Keytruda') every three weeks. Is it hel...
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.